A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma

[1]  M. Nykter,et al.  Genetic and epigenetic characteristics of inflammatory bowel disease associated colorectal cancer. , 2021, Gastroenterology.

[2]  S. Bicciato,et al.  Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ , 2021, Nature Communications.

[3]  Xiao-na Hu,et al.  Hypoxia-dependent expression of MAP17 coordinates the Warburg effect to tumor growth in hepatocellular carcinoma , 2021, Journal of experimental & clinical cancer research : CR.

[4]  Jeffrey S. Morris,et al.  Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer , 2020, Gut.

[5]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[6]  Martin J. Aryee,et al.  Large-Scale Topological Changes Restrain Malignant Progression in Colorectal Cancer , 2020, Cell.

[7]  Y. Cho,et al.  Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer , 2020, Nature Genetics.

[8]  A. Jemal,et al.  Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[9]  Kathleen M. Jagodnik,et al.  ChEA3: transcription factor enrichment analysis by orthogonal omics integration , 2019, Nucleic Acids Res..

[10]  Stefan Schoenfelder,et al.  Long-range enhancer–promoter contacts in gene expression control , 2019, Nature Reviews Genetics.

[11]  Joshua M. Korn,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[12]  P. Sorensen,et al.  Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance , 2019, Proceedings of the National Academy of Sciences.

[13]  Andrew R. Morton,et al.  Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma , 2019, The Journal of experimental medicine.

[14]  Andrew R. Morton,et al.  Mismatch repair-signature mutations activate gene enhancers across human colorectal cancer epigenomes , 2019, eLife.

[15]  Christopher J. Ott,et al.  Small-molecule targeting of brachyury transcription factor addiction in chordoma , 2019, Nature Medicine.

[16]  Matthias Ernst,et al.  Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map , 2018, Nature Reviews Cancer.

[17]  Mauro A. A. Castro,et al.  The chromatin accessibility landscape of primary human cancers , 2018, Science.

[18]  J. Ramalho,et al.  The Na+‐coupled glucose transporter SGLT2 interacts with its accessory unit MAP17 in vitro and their expressions overlap in the renal proximal tubule , 2018, FEBS letters.

[19]  S. Shousha,et al.  Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer , 2018, Nature Medicine.

[20]  Henry W. Long,et al.  A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer , 2018, Cell.

[21]  J. Rabinowitz,et al.  Metabolomics and Isotope Tracing , 2018, Cell.

[22]  M. Karin,et al.  NF-κB, inflammation, immunity and cancer: coming of age , 2018, Nature Reviews Immunology.

[23]  James J. Morrow,et al.  Positively selected enhancer elements endow osteosarcoma cells with metastatic competence , 2017, Nature Medicine.

[24]  Anne Song,et al.  Therapeutic Targeting of Ependymoma as Informed by Oncogenic Enhancer Profiling , 2017, Nature.

[25]  J. Michael Cherry,et al.  The Encyclopedia of DNA elements (ENCODE): data portal update , 2017, Nucleic Acids Res..

[26]  Aviad Tsherniak,et al.  Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. , 2017, Cancer discovery.

[27]  E. Bernstein,et al.  Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. , 2017, Molecular cell.

[28]  Swe Swe Myint,et al.  VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. , 2017, Cancer discovery.

[29]  Kathleen M Jagodnik,et al.  Massive mining of publicly available RNA-seq data from human and mouse , 2017, Nature Communications.

[30]  T. Ushijima,et al.  Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway. , 2017, Cancer letters.

[31]  Takafumi N. Yamaguchi,et al.  TMPRSS2–ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer , 2017, Nature Genetics.

[32]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.

[33]  Geet Duggal,et al.  Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference , 2017, Nature Methods.

[34]  James J. Morrow,et al.  Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome , 2017, Nature Communications.

[35]  J. Guinney,et al.  Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer , 2017, Nature Reviews Cancer.

[36]  Katherine C. Sexton,et al.  Genomic regulation of invasion by STAT3 in triple negative breast cancer , 2016, Oncotarget.

[37]  D. Bichet,et al.  MAP17 Is a Necessary Activator of Renal Na+/Glucose Cotransporter SGLT2. , 2017, Journal of the American Society of Nephrology : JASN.

[38]  K. Soo,et al.  Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity , 2016, Nature Communications.

[39]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[40]  Roland Eils,et al.  Active medulloblastoma enhancers reveal subgroup-specific cellular origins , 2016, Nature.

[41]  Oleg Mayba,et al.  CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. , 2016, The Journal of clinical investigation.

[42]  Marcin Imielinski,et al.  Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers , 2015, Nature Genetics.

[43]  Eugenia G. Giannopoulou,et al.  Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH , 2015, Science.

[44]  Timothy E. Reddy,et al.  Highly Specific Epigenome Editing by CRISPR/Cas9 Repressors for Silencing of Distal Regulatory Elements , 2015, Nature Methods.

[45]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[46]  S. Mandrup,et al.  Acute TNF-induced repression of cell identity genes is mediated by NFκB-directed redistribution of cofactors from super-enhancers , 2015, Genome research.

[47]  A. van Oudenaarden,et al.  Ascl2 acts as an R-spondin/Wnt-responsive switch to control stemness in intestinal crypts. , 2015, Cell stem cell.

[48]  Y. Luqmani,et al.  Phosphofructokinase: a mediator of glycolytic flux in cancer progression. , 2014, Critical reviews in oncology/hematology.

[49]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[50]  R. Young,et al.  An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element , 2014, Science.

[51]  Hua Yu,et al.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.

[52]  N. Hay,et al.  The pentose phosphate pathway and cancer. , 2014, Trends in biochemical sciences.

[53]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[54]  E. Larsson,et al.  Antioxidants Accelerate Lung Cancer Progression in Mice , 2014, Science Translational Medicine.

[55]  Charles Y. Lin,et al.  Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. , 2013, Cancer cell.

[56]  R. Young,et al.  Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.

[57]  Eugenia G. Giannopoulou,et al.  Synergistic activation of inflammatory cytokine genes by interferon-γ-induced chromatin remodeling and toll-like receptor signaling. , 2013, Immunity.

[58]  A. Yoshimura,et al.  SOCS, inflammation, and cancer , 2013, JAK-STAT.

[59]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[60]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[61]  Juan J. Marin,et al.  MAP17 and SGLT1 Protein Expression Levels as Prognostic Markers for Cervical Tumor Patient Survival , 2013, PloS one.

[62]  Linda C Hsieh-Wilson,et al.  Phosphofructokinase 1 Glycosylation Regulates Cell Growth and Metabolism , 2012, Science.

[63]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[64]  Jason H. Moore,et al.  Epigenomic Enhancer Profiling Defines a Signature of Colon Cancer , 2012, Science.

[65]  J. Asara,et al.  A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue , 2012, Nature Protocols.

[66]  P. Dervan,et al.  Modulation of NF-κB-dependent gene transcription using programmable DNA minor groove binders , 2011, Proceedings of the National Academy of Sciences.

[67]  Helge G. Roider,et al.  Transcription factor binding predictions using TRAP for the analysis of ChIP-seq data and regulatory SNPs , 2011, Nature Protocols.

[68]  A. Subramanian,et al.  Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress , 2011, Proceedings of the National Academy of Sciences.

[69]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[70]  M. Karin,et al.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.

[71]  R. Santer,et al.  Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. , 2010, American Society of Nephrology. Clinical Journal.

[72]  J. Marshall.  Coming of age. , 2008, Surgical infections.

[73]  Michael D. Connolly,et al.  Use of Ly6G‐specific monoclonal antibody to deplete neutrophils in mice , 2008, Journal of leukocyte biology.

[74]  J. Leal,et al.  MAP17 enhances the malignant behavior of tumor cells through ROS increase. , 2007, Carcinogenesis.

[75]  J. Leal,et al.  MAP17 overexpression is a common characteristic of carcinomas. , 2007, Carcinogenesis.

[76]  Allen D. Delaney,et al.  Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing , 2007, Nature Methods.

[77]  A. Carnero,et al.  Large scale genetic screen identifies MAP17 as protein bypassing TNF‐induced growth arrest , 2007, Journal of cellular biochemistry.

[78]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[79]  B. Göttgens,et al.  Transcriptional Regulation of the SCL Locus: Identification of an Enhancer That Targets the Primitive Erythroid Lineage In Vivo , 2005, Molecular and Cellular Biology.

[80]  Kurt Zatloukal,et al.  Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. , 2005, Neoplasia.

[81]  E. Suh,et al.  The role of Cdx proteins in intestinal development and cancer , 2004, Cancer biology & therapy.

[82]  J. Catalán,et al.  Rat kidney MAP17 induces cotransport of Na-mannose and Na-glucose in Xenopus laevis oocytes. , 2003, American journal of physiology. Renal physiology.

[83]  Michael Field,et al.  Intestinal ion transport and the pathophysiology of diarrhea. , 2003, The Journal of clinical investigation.

[84]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[85]  P. Traber,et al.  Cdx1 and cdx2 expression during intestinal development. , 2000, Gastroenterology.

[86]  N. Comella,et al.  Identification and partial characterization of PDZK1: a novel protein containing PDZ interaction domains. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[87]  O. Kocher,et al.  Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[88]  D. Simmons,et al.  Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. , 1993, Blood.

[89]  L. Cantley,et al.  Rapid release of bound glucose-6-phosphate dehydrogenase by growth factors. Correlation with increased enzymatic activity. , 1991, The Journal of biological chemistry.